Ho Chi Minh City, 12 July – Gene Solutions’ R&D team is honored to be selected to receive the Conquer Cancer® Merit Award at the 2024 ASCO Breakthrough Meeting. The award was presented to our “K-DETEK” clinical validation study of a multimodal liquid biopsy–based assay, Screening for the Presence of Tumor by Methylation and Size (SPOT-MAS) – Abstract title: Comprehensive validation of a cell-free DNA-based assay for multi-cancer detection: A Vietnamese longitudinal prospective cohort study of 9,024 participants. (Clinical Trial Identifier: NCT05227261)
The Conquer Cancer® Merit Awards is granted to eligible researchers whose research is addressed in high-quality abstracts submitted to an ASCO Meeting and recognized for its scientific merit. This recognition highlights our unwavering commitment to advancing cancer research and improving patient outcomes.
Le Son Tran, Principal Investigator for SPOT-MAS, expressed gratitude for this recognition, stating, “We are deeply honoured to receive the Merit Award from Conquer Cancer Foundation. This award is a testament to the hard work and dedication of our entire SPOT-MAS team. Our team is committed to pioneering research to allow us to look further ahead for cancer signals. We are motivated to continue our mission of making significant strides in MCED – with the vision of revolutionizing cancer diagnosis by enabling earlier intervention and treatment.”
In 2023, the SPOT-MAS research team was featured in the ASCO Breakthrough Press Conference on Aug 3, 2023, where interim results demonstrated that next generation ctDNA screening using the SPOT-MAS blood test held promise as an early detection tool.
Conquer Cancer® awardees will present their research in Yokohama, Japan, August 8–10, 2024, during ASCO Breakthrough, a yearly oncology meeting bringing together thought leaders, clinicians, technology pioneers, novel drug developers and researchers. Medical Genetics Institute and SPOT-MAS R&D team have a total of 4 posters accepted at 2024 ASCO Breakthrough Meeting and our team looks forward to meeting with prospective collaborators and oncology practitioners in Yokohama.
About Gene Solutions:
Gene Solutions is a leading genetic testing company in South-East Asia that empowers healthcare decisions with accessible and critical insights. The company enables access to next-generation genetic tests that support reproductive health and clinical oncology. Gene Solutions provides personalized minimal residual disease (MRD) detection, comprehensive genomic profiling (CGP) and multi-cancer early detection (MCED) tests using advanced ctDNA technology for oncology. With six international Next-Generation Sequencing (NGS) Laboratories in Southeast Asia, Gene Solutions is committed to enhancing healthcare with their innovative genetic solutions.
About ASCO:
Founded in 1964, the American Society of Clinical Oncology, Inc. (ASCO®) is committed to making a world of difference in cancer care. As the world’s leading organization of its kind, ASCO represents more than 45,000 oncology professionals who care for people living with cancer. Through research, education, and promotion of the highest-quality patient care, ASCO works to conquer cancer and create a world where cancer is prevented or cured, and every survivor is healthy. ASCO is supported by its affiliate organization, the Conquer Cancer Foundation. Learn more at www.ASCO.org.
Media Contact:
- Ms. Jean Huang
- [email protected]
For more information about the 2024 ASCO Breakthrough Conference, please visit https://conferences.asco.org/breakthrough/welcome
Medical Genetics Institute, Ho Chi Minh City and Gene Solutions thank Conquer Cancer Foundation and the ASCO community for this recognition and looks forward to continuing its efforts in making impactful contributions to cancer research and patient care.
